Table 2.
18F-fluoride uptake around cages in 20 patients with 30 cervical and/or lumbar intercorporal fusions
| Patient no. | Segment cervical spine | Segment lumbar spine | Time in months between last intercorporal intervention and PET/CT | Increased uptake, yes (1)/no (0) | Materiala |
|---|---|---|---|---|---|
| 1 | C4/5, 5/6, 6/7 | – | 92 (3×) | 0, 0, 1 | ID HWS Cage, Titanium (3×) |
| 2 | – | L5/S1 (left) | 17 | 1 | Telamon Titanium |
| 3 | C5/6, 6/7 | – | 30 (2×) | 1, 1 | ID HWS Cage, Titanium (2×) |
| 4 | – | L4/5 | 13 | 1 | Telamon Titanium |
| 5 | – | L4/5, L5/S1 | 102 (L4/5), 35 (L5/S1) | 0, 0 | ProSpace Titanium, Telamon Titanium |
| 6 | – | L4/5 | 107 | 0 | ProSpace Titanium |
| 7 | C5/6 | L2/3, L4/5 | 37 (C5/6), 2 (L2/3), 69 (L4/5) | 1, 1, 0 | ID HWS Cage, Titanium, KZC, Titaniumb, ProSpace Titanium |
| 8 | C3/4, C4/5 | L5/S1 | 79 (C3–5), 80 (L5/S1) | 1, 1, 0 | ID HWS Cage, Titanium (2×), ProSpace Titanium |
| 9 | – | L4/5 | 47 | 1 | Telamon Titanium |
| 10 | – | L5/S1 | 27 | 1 | Telamon Titanium |
| 11 | C5/6 | – | 90 | 0 | ID HWS Cage, Titanium |
| 12 | – | L5/S1 | 112 | 0 | Diapason Titanium |
| 13 | – | L4/5 | 19 | 0 | Telamon Titanium |
| 14 | – | L4/5 | 100 | 0 | ProSpace Titanium |
| 15 | C5/6, C6/7 | – | 34 (2×) | 0, 0 | ID HWS Cage, Titanium (2×) |
| 16 | – | L5/S1 | 116 | 1 | Harms Titanium |
| 17 | – | L5/S1 | 74 | 1 | ProSpace Titanium |
| 18 | C5/6 | – | 84 | 1 | ID HWS Cage, Titanium |
| 19 | C5/6 | L3/4 | 91 (C5/6), 106 (L3/4) | 0, 0 | ID HWS Cage, Titanium, ProSpace Titanium |
| 20 | – | L5/S1 | 14 | 1 | ProSpace Titanium |
ID Implant design
aMaterial named includes registered trademarks ®
bKZC Karl Zweifel Cage